Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Corporate Update (Oct 27, 2025)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed October 27, 2025
Period End
October 27, 2025
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed October 27, 2025. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) furnished a Form 8-K on October 27, 2025 under Item 8.01 (Other Events) to report positive topline results from FORTIFY, its randomized, double-blind, placebo-controlled Phase 3 pivotal study of BBP-418, an investigational small molecule oral therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

The press release, attached as Exhibit 99.1, states that all primary and secondary interim analysis endpoints were achieved, with a well-tolerated safety profile consistent with prior studies and no new or unexpected safety findings. The primary interim analysis endpoint, glycosylated alpha-dystroglycan (αDG), increased by 1.8xa from baseline at 3 months versus approximately no change in the placebo group (p<0.0001), and the increase was sustained at 12 months (p<0.0001). Average serum creatine kinase, a marker of muscle breakdown, fell 82% from baseline at 12 months (p<0.0001).

Key clinical endpoints at 12 months also improved: 100-meter timed test velocity rose 0.14 m/s from baseline and 0.27 m/s versus placebo (p<0.0001), and FVC rose about 3%b predicted from baseline with a difference of about 5% predicted versus placebo (p=0.0071). BridgeBio intends to engage the FDA later in 2025 and plans to submit a New Drug Application for BBP-418 in the first half of 2026.

The company states that full interim analysis data are still being analyzed and that detailed results will be presented at a future medical meeting. The filing notes that BBP-418 holds Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA and Orphan Drug Designation from the EMA, and that BridgeBio may qualify for a Priority Review Voucher if the drug is approved.

Key Highlights

  1. FORTIFY Phase 3 study of BBP-418 met all primary and secondary interim analysis endpoints, with a well-tolerated safety profile.
  2. Glycosylated αDG increased 1.8x from baseline at 3 months versus approximately no change in placebo (p<0.0001), sustained at 12 months (p<0.0001).
  3. Serum creatine kinase (CK) decreased an average of 82% from baseline at 12 months, statistically significant versus placebo (p<0.0001).
  4. 100MTT ambulatory velocity increased 0.14 m/s from baseline and 0.27 m/s versus placebo at 12 months (p<0.0001).
  5. FVC increased about 3% predicted from baseline and about 5% predicted versus placebo at 12 months (p=0.0071).
  6. Company plans to engage the FDA later in 2025 and submit an NDA for BBP-418 in the first half of 2026.
  7. BBP-418 holds Orphan Drug, Fast Track, and Rare Pediatric Disease Designations (FDA) and Orphan Drug Designation (EMA); may qualify for a Priority Review Voucher if approved.

Frequently Asked Questions

  1. What did BridgeBio announce about BBP-418?

    BridgeBio reported positive topline interim results from the Phase 3 FORTIFY study of BBP-418, an investigational oral small molecule for LGMD2I/R9. All primary and secondary interim analysis endpoints were achieved, and the company described the safety profile as well-tolerated and consistent with prior studies.

  2. What were the primary efficacy results?

    The primary interim analysis endpoint, glycosylated αDG, rose 1.8x from baseline at 3 months versus approximately no change in the placebo group (p<0.0001), and the increase was sustained at 12 months (p<0.0001). The filing notes this corresponds to about 17% of control.

  3. What are the regulatory next steps?

    BridgeBio intends to engage the FDA later in 2025 to discuss the data and plans for a New Drug Application (NDA) for BBP-418, which it plans to submit in the first half of 2026. Detailed results are to be presented at a future medical meeting.

  4. What clinical benefits were observed at 12 months?

    Ambulatory function (100MTT) velocity increased 0.14 m/s from baseline and 0.27 m/s versus placebo (p<0.0001). Pulmonary function (FVC) increased about 3% predicted from baseline and differed by about 5% predicted versus placebo (p=0.0071). Serum CK fell an average of 82% from baseline (p<0.0001).

  5. Are there any potential regulatory incentives for BBP-418?

    BBP-418 has Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA, plus Orphan Drug Designation from the EMA. Consistent with the Rare Pediatric Disease Designation, BridgeBio may qualify for a Priority Review Voucher if BBP-418 is approved.